Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.

Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

AMP Case Reports

AMP case report: Is undifferentiated sarcoma with EWSR1-POU5F1 fusion a molecularly defined entity?

September 2026—About 30 percent of soft tissue sarcomas are associated with chromosomal translocations leading to the formation of chimeric fusion genes that modify cellular function, leading to dysregulation of proliferation and resulting in clinically and genetically distinct neoplasms. EWSR1 is a commonly rearranged gene in sarcomas that can fuse as the 5’ partner with various genes. EWSR1-rearranged sarcomas include angiomatoid fibrous histiocytoma, clear cell sarcoma of soft parts, Ewing sarcoma, desmoplastic small round cell tumor (DSRCT), extraskeletal myxoid chondrosarcoma, myxoid liposarcoma, clear cell sarcoma-like tumors of the gastrointestinal tract, as well as round cell sarcoma with EWSR1-non-ETS fusions. Herein, we report an unusual case of EWSR1-POU5F1 fusion in an undifferentiated sarcoma. It has previously been described in myoepithelial tumors,3 but it has been described in undifferentiated sarcomas only a couple of times in the literature, to the best of our knowledge.

AMP case report: Therapy-related acute myeloid leukemia in a patient with BRCA1-positive breast cancer and a DDX41 possibly germline variant

August 2026—The 2022 World Health Organization and International Consensus Classification frameworks recognize several well-defined myeloid neoplasm categories that arise in the setting of inherited genetic predisposition. These entities are grouped according to associated clinical features and include myeloid neoplasms with germline predisposition in the absence of antecedent platelet abnormalities or organ dysfunction (e.g. CEBPA, DDX41, and TP53), those associated with inherited platelet disorders (e.g. RUNX1, ANKRD26, and ETV6), and disorders linked to underlying or potential organ dysfunction.

AMP case report: Ultra-hypermutated colorectal adenocarcinoma identified at relapse

June 2026—We present the case of a 75-year-old woman with a history of a pT4 colorectal adenocarcinoma who was status-post right hemicolectomy two years prior to the current care episode. She returned for urgent medical evaluation of recurrent abdominal pain, was diagnosed with a small bowel obstruction, and underwent exploratory laparotomy with small bowel resection and primary anastomosis.

AMP case report: Identifying the signal in the signal: incidental detection of B-cell lymphoproliferative disorder-related variants in the molecular profiling of a spindle cell sarcoma

July 2025—We report the case of a 75-year-old female who initially presented with a 10-cm left pretibial mass on MRI. A biopsy revealed a high-grade spindle cell sarcoma with myofibroblastic differentiation. PET CT showed intense uptake in osseous lesions at the scapula, vertebral bodies, iliac bones, sacrum, and femoral head. A sacrum biopsy confirmed metastatic spindle cell sarcoma. The patient underwent chemotherapy and radiotherapy. A follow-up CT scan several months later revealed new liver and lung metastases, prompting molecular analysis of the sacrum specimen.

AMP case report: Use of molecular techniques to solve a challenging case of primary cutaneous marginal zone lymphoma

April 2024—Primary cutaneous marginal zone lymphoma (PCMZL) is a newly recognized, distinctive subtype of non-Hodgkin’s lymphoma. This low-grade lymphoma predominantly presents as papules or nodules within the skin of middle-aged adults. Formerly grouped under the extranodal marginal zone lymphoma (EMZL) category, the World Health Organization’s fifth edition classification of hematolymphoid tumors now recognizes PCMZL as a distinct entity.

AMP case report: Acute myeloid leukemia with hyperdiploidy

March 2024—CAP TODAY and the Association for Molecular Pathology have teamed up to bring molecular case reports to CAP TODAY readers. AMP members write the reports using clinical cases from their own practices that show molecular testing’s important role in diagnosis, prognosis, and treatment. This month’s report comes from Aga Khan University in Karachi, Pakistan. Case. An 87-year-old male with a clinical history of hypertension and sick sinus syndrome presented with a one-month history of fever, generalized weakness, and weight loss. There was no lymphadenopathy or hepatosplenomegaly on physical examination. Bone marrow examination was performed to evaluate for cytopenias.

Potential von Hippel-Lindau syndrome in a patient with negative germline testing

CAP TODAY and the Association for Molecular Pathology have teamed up to bring molecular case reports to CAP TODAY readers. AMP members write the reports using clinical cases from their own practices that show molecular testing’s important role in diagnosis, prognosis, and treatment. The following report comes from Washington University School of Medicine in St. Louis. If you would like to submit a case report, please send an email to the AMP at amp@amp.org. For more information about the AMP and all previously published case reports, visit www.amp.org.

MARKETPLACE

TRENDING